Clinigen Group PLC Company Profile (LON:CLIN)

Analyst Ratings

Consensus Ratings for Clinigen Group PLC (LON:CLIN) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 803

Analysts' Ratings History for Clinigen Group PLC (LON:CLIN)
Show:
DateFirmActionRatingPrice TargetActions
7/20/2016Stifel NicolausReiterated RatingBuyGBX 800View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016Numis Securities LtdReiterated RatingBuyGBX 916View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2016Peel HuntReiterated RatingBuyGBX 1,000View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/20/2016Royal Bank Of CanadaLower Price TargetOutperformGBX 770 -> GBX 750View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015N+1 SingerReiterated RatingBuyGBX 549View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/17/2015InvestecBoost Price TargetHoldGBX 546 -> GBX 550View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Clinigen Group PLC (LON:CLIN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Clinigen Group PLC (LON:CLIN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Clinigen Group PLC (LON:CLIN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
3/2/2016GBX 1.300.2%3/17/20163/17/20164/8/2016Tweet This Announcement  Share This Announcement on StockTwits
9/22/2015GBX 2.300.32%10/15/201510/15/201511/6/2015Tweet This Announcement  Share This Announcement on StockTwits
9/24/2014GBX 2.100.46%10/16/201410/16/201411/7/2014Tweet This Announcement  Share This Announcement on StockTwits
2/26/2014GBX 10.19%3/5/20143/5/20143/28/2014Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Clinigen Group PLC (LON:CLIN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/16/2016Abell,MartinInsiderBuy11,296GBX 518£58,513.28Tweet This Trade  Share This Trade on StockTwits
10/7/2015Edward Chilton,ShaunInsiderSell412,778GBX 685£2,827,529.30Tweet This Trade  Share This Trade on StockTwits
6/3/2015John HartupInsiderSell23,934GBX 644£154,134.96Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Clinigen Group PLC (LON:CLIN)
DateHeadline
07/22/16 11:16 AMClinigen on track for £1bln market cap - CEO
07/21/16 08:46 PMClinigen Group (LON:CLIN) stock price target held steady at 1,000GBX as issued in a report today by Peel Hunt
07/20/16 04:21 PMClinigen : Revenue And Profit Surge On Acquisitions, Organic Growth
07/20/16 04:21 PMA statement released today by Numis about Clinigen Group(LON:CLIN) maintains the target price at 916GBX
07/20/16 04:21 PMClinigen Group well positioned after "transformational" year
07/08/16 08:19 PMClinigen Group Issues 83,016 Shares In Option Exercise (ALLISS)
07/07/16 10:49 AMClinigen : Issues 83,016 Shares In Option Exercise (ALLISS)
07/01/16 02:41 AMClinigen Group - Notice of Trading Update - [at noodls] - Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, will announce a full year trading update for the 12 months ended 30 June 2016 on Wednesday 20 ...
06/30/16 03:30 PMHorizon Pharma (HZNP) Announces Submission of RAVICTI sNDA o Expand Age Range for Management of Urea Cycle Disorders
06/30/16 03:30 PMHuman Papillomavirus and Cytomegalovirus Therapeutics Market Detailed Analysis and Forecast by 2020
06/29/16 11:22 AMClinigen's Idis Starts Managed Access Programme For Horizon's Ravicti
06/29/16 11:22 AMClinigen : and Horizon Pharma enter partnership to initiate European Managed Access program for RAVICTI® (glycerol phenylbutyrate) Oral Liquid
06/29/16 11:22 AMClinigen to manage access for Horizon drug
06/24/16 03:22 PMClinigen Group (LON:CLIN) target price maintained to GBX0 as announced today by Numis
06/24/16 03:39 AMClinigen Group Plc breached its 50 day moving average in a Bullish Manner : CLIN-GB : June 24, 2016 -
06/16/16 07:38 AMClinigen signs exclusive global supply pact with Galen for chemotherapy drug, DaunoXome
06/14/16 03:10 PMClinigen : Clinigen and Galen enter exclusive Global Access agreement for chemotherapydrug DaunoXome®
06/14/16 03:10 PMClinigen Inks Global Access Pact for Chemotherapy Drug DaunoXome
06/14/16 03:10 PMClinigen signs exclusive global access agreement for cancer treatment
06/14/16 01:39 PM[$$] Clinigen Inks Global Access Pact for Chemotherapy Drug -
06/14/16 03:19 AMClinigen Group - Clinigen and Galen enter exclusive Global Access agreement for chemotherapydrug DaunoXome® - [at noodls] - Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, announces that its Idis Global Access (GA) division has signed an exclusive supply agreement with ...
06/14/16 01:09 AMClinigen and Galen enter exclusive Global Access agreement for chemotherapy drug DaunoXome® - [at noodls] - Under the terms of the supply agreement, Idis GA will provide Galen's chemotherapy drug DaunoXome® to Healthcare Professionals on an on-demand basis in 20 European countries, Australia, New Zealand and ...
06/13/16 03:38 AMClinigen Group Plc breached its 50 day moving average in a Bullish Manner : CLIN-GB : June 13, 2016 -
06/11/16 11:29 AMClinigen now has a “complete global reach”, says chief
06/09/16 09:32 AMClinigen sets up managed access in Europe for fungal drug
06/09/16 01:09 AMClinigen announces partnership with Basilea to initiate a Managed Access program for isavuconazole to treat patients with invasive fungal infections in Europe - [at noodls] - Isavuconazole is an intravenous and oral triazole antifungal indicated for the treatment of adult patients with invasive aspergillosis and adult patients with mucormycosis for whom amphotericin B is inappropriate. ...
06/02/16 03:36 AMClinigen Group Plc breached its 50 day moving average in a Bearish Manner : CLIN-GB : June 2, 2016 -
05/19/16 07:32 AMClinigen expands US presence with opening of new Yardley headquarters - [at noodls] - The office in Yardley, PA combines the Group's existing operations in Philadelphia, PA and Princeton, NJ following Clinigen's acquisition of Idis in April 2015, providing a dedicated base for the Group's ...
05/10/16 07:18 AMExclusive US commercialisation agreement for Ethyol - [at noodls] - For Immediate Release 10 May 2016 Clinigen Group and Cumberland Pharmaceuticals enter into exclusive U.S. commercialisation agreement for oncology support drug Ethyol® Clinigen Group plc (AIM: CLIN, 'Clinigen' ...
03/14/16 12:47 PMRecent Broker Updates On Clinigen Group (LON:CLIN) - Risers & Fallers - Recent Broker Updates On Clinigen Group (LON:CLIN)Risers & FallersClinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates ...and more »
03/02/16 06:07 AMHalf Year 2016 Clinigen Group PLC Earnings Release - Before Market Open -
03/02/16 01:11 AMClinigen Acquires US-Approved Totect® (dexrazoxane) from Biocodex to Become the Only Global Source for the Treatment of Anthracycline Extravasation -
03/02/16 01:10 AMClinigen Group plc: Continued Strong Growth with EPS up 21% -
02/26/16 10:42 AMWere Analysts Bearish Clinigen Group PLC (LON:CLIN) This Week? - RiversideGazette.com - Were Analysts Bearish Clinigen Group PLC (LON:CLIN) This Week?RiversideGazette.comOut of 6 analysts covering Clinigen Group (LON:CLIN), 6 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Clinigen Group was the topic in 16 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Below is a list ...
02/15/16 01:19 PMWere Analysts Bullish Clinigen Group PLC (LON:CLIN) This Week? - Sonoran Weekly Review - Were Analysts Bullish Clinigen Group PLC (LON:CLIN) This Week?Sonoran Weekly ReviewOut of 6 analysts covering Clinigen Group (LON:CLIN), 6 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Clinigen Group was the topic in 15 analyst reports since July 29, 2015 according to StockzIntelligence Inc. Below is a list ...
02/09/16 01:12 PMAnalysts Consensus For Clinigen Group (LON:CLIN) - Risers & Fallers - Analysts Consensus For Clinigen Group (LON:CLIN)Risers & FallersClinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates ...and more »
02/05/16 12:52 PMClinigen Group Plc (CLIGF) - Clinigen Group plc provides specialty pharmaceutical products and services in the United Kingdom and internationally. The company s Clinical Trials Supply business supplies and manages commercial medical products, such as comparator drugs, adjuvant drugs ...
02/04/16 12:46 PMClinigen Group plc (CLIN) - Clinigen Group plc (the "Company", AIM: CLIN) announces that it has made an application for the admission to trading on AIM of 1,874 ordinary shares of 0.1 pence each in the Company (the "New Ordinary Shares"), which have been issued to satisfy the ...
01/22/16 06:26 PMClinigen Group (LON:CLIN) Receives Buy Rating From Numis Analysts - Risers & Fallers - Clinigen Group (LON:CLIN) Receives Buy Rating From Numis AnalystsRisers & FallersClinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates ...and more »
01/20/16 11:19 AMClinigen Group PLC 52.6% Potential Upside Indicated by Numis - DirectorsTalk Interviews - Risers & FallersClinigen Group PLC 52.6% Potential Upside Indicated by NumisDirectorsTalk InterviewsClinigen Group PLC using EPIC/TICKER code LON:CLIN had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' today by analysts at Numis. Clinigen Group PLC are listed in the Health Care sector within AIM. Numis have set a ...RBC Capital Markets Indicates Potential 28.21% Increase In Shares Of Clinigen GroupRisers & Fallersall 2,726 news articles »
01/19/16 10:56 AMClinigen Group PLC 56.5% Potential Upside Indicated by Peel Hunt - DirectorsTalk Interviews - Risers & FallersClinigen Group PLC 56.5% Potential Upside Indicated by Peel HuntDirectorsTalk InterviewsClinigen Group PLC with EPIC/TICKER LON:CLIN had its stock rating noted as 'Reiterates' with the recommendation being set at 'BUY' this morning by analysts at Peel Hunt. Clinigen Group PLC are listed in the Health Care sector within AIM. Peel Hunt have ...Clinigen Group PLC (CLIN) Earns Buy Rating from Peel HuntIntercooler FinancialClinigen Group reiterated as Buy By StifelRisers & FallersClinigen First Half Solid With Revenue And Profit Up On AcquisitionsLondon South East (registration) (blog)all 18 news articles »
01/19/16 10:56 AMRevenue up by 116% at Clinigen Group as acquisitions kick in - BURTON-upon-Trent pharmaceuticals plc Clinigen Group has seen its revenue increase by 116% and its gross profit surge by 100% in the first half of its trading year. In an update to the London Stock Exchange this morning covering the six months to December ...
01/19/16 06:15 AMHalf year trading update - [at noodls] - 19 January 2016 Clinigen Group plc Solid H1 performance, integration of recent acquisitions on track and well positioned for good H2 Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global ...
01/19/16 04:06 AMClinigen Group's acquisitions boost first half growth -
01/15/16 03:32 AMClinigen Group Plc breached its 50 day moving average in a Bearish Manner : January 15, 2016 -
12/03/15 06:27 AMClinigen Group Partners with Sunesis to Initiate a Compassionate Use Program for Patients with Relapsed or Refractory Acute Myeloid Leukemia - [at noodls] - Vosaroxin is an investigational treatment and is currently not approved for use by any regulatory agency. Compassionate use programs are put in place to provide access to medicines for patients who have ...
12/03/15 06:27 AMSunesis Partners With Clinigen Group to Initiate a Compassionate Use Program for Patients With Relapsed or Refractory Acute Myeloid Leukemia - [at noodls] - SOUTH SAN FRANCISCO, Calif., Dec. 3, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that it has initiated a Compassionate Use Program for vosaroxin. The Compassionate ...
11/30/15 02:26 AMClinigen Group Initiates Managed Access Program for Ixazomib for Patients with Multiple Myeloma - [at noodls] - Ixazomib was approved by the US Food and Drug Administration (FDA) on 20 November 2015 under the trade name NINLARO (ixazomib) capsules after receiving Priority Review status in September. The European ...
11/24/15 01:43 AMClinigen Group extends exclusive clinical trial distribution agreement with Accord Healthcare for another two years - [at noodls] - The agreement has also been extended to include four new products including the solid dose oncology drug temozolomide and Accord's first biosimilar, Accofil® (filgrastim) for the treatment of chemotherapy-induced ...
11/20/15 01:04 PMClinigen Group Plc – Value Analysis (LONDON:CLIN) : November 20, 2015 -

Social

About Clinigen Group PLC

Clinigen Group PLC logoClinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP). The CTS segment sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies. The MA segment specializes in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies. The GA segment provides ethical access to post approval and short-supply medicines, in regions where patients have low or non-existent access to these often-essential drugs. The SP segment manufactures and distributes its own and in-license specialist, hospital-only medicines.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: CLIN
  • CUSIP:
Key Metrics:
  • Previous Close: $8.94
  • 50 Day Moving Average: $578.57
  • 200 Day Moving Average: $591.65
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $752.74M
  • Current Year EPS Consensus Estimate: $N/A EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: